Back to top
more

BioTechne Corp (TECH)

(Real Time Quote from BATS)

$54.80 USD

54.80
622,336

-0.08 (-0.15%)

Updated Aug 5, 2025 12:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?

by Zacks Equity Research

TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.

Zacks Equity Research

INCY or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

INCY vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock

by Zacks Equity Research

TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.

Zacks Equity Research

Why Is Techne (TECH) Down 3% Since Last Earnings Report?

by Zacks Equity Research

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is Bio-Techne Stock the Right Pick for Your Portfolio Now?

by Zacks Equity Research

TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today?

Zacks Equity Research

Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket

by Zacks Equity Research

TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.

Zacks Equity Research

Techne (TECH) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Is the Options Market Predicting a Spike in BioTechne Stock?

by Zacks Equity Research

Investors need to pay close attention to TECH stock based on the movements in the options market lately.

Zacks Equity Research

Techne (TECH) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 9.80% and 0.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline

by Zacks Equity Research

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of -53.57% and 3.22%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

TECH Gears Up to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.

Zacks Equity Research

Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?

by Zacks Equity Research

Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Bio-Techne Opens New Customer Experience Centre in Germany

by Zacks Equity Research

TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

Zacks Equity Research

TECH Stock Might Rise Following the Leo Shipping Announcement

by Zacks Equity Research

Bio-Techne begins to ship the Leo System - the next-generation high throughput simple western platform.

Zacks Equity Research

Techne (TECH) Down 15.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?

by Zacks Equity Research

Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.

Zacks Equity Research

EXEL or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu

by Zacks Equity Research

TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.

Zacks Equity Research

EXEL or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket

by Zacks Equity Research

TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.

Zacks Equity Research

Techne (TECH) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 10.53% and 4.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Boston Scientific, Hologic, BioTechne, STERIS and Align

by Zacks Equity Research

Boston Scientific, Hologic, BioTechne, STERIS and Align are included in this Analyst Blog.